BioSpace News Archive

The US Food and Drug Administration has cleared a Numares Health test, the AXINON® LDL-p Test System, as a new tool physicians can use to measure lipoproteins for patients at risk for cardiovascular disease.

NK:IO, a leader in natural killer cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2M.

MindBio Therapeutics Corp. is pleased to have started selection of participants for its Phase 2 randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of Lysergic Acid Diethylamide (LSD) and Meaning Centred Psychotherapy in a world’s first LSD take-home 6-week trial involving a total of 40 participants.

Bionomics Limited announced that it has submitted a formal request to the Australian Securities Exchange to be removed from the official list of the ASX, in keeping with the Company’s ongoing transformation to a U.S. focused organization.

SamanTree Medical, a medical technology company specializing in innovative solutions to improve cancer treatment, is thrilled to announce the appointment of Mr. Olivier Delporte as the new Chief Executive Officer, effectively immediately.

Danaher Corporation announced results for the second quarter 2023. Net earnings refer to net earnings attributable to common shareholders.

In the second quarter, the actions we took to strengthen our supply chain and restructure the company led to improved service for customers, reduced costs across 3M, and better than expected margins and cash flow,” said Mike Roman, 3M chairman and chief executive officer.

GE HealthCare, a leading global precision care innovator, reported financial results for the second quarter ended June 30, 2023.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2023, at 8:00 a.m. EDT to review business updates and its second quarter 2023 financial results.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis.